HAS Healthcare Advanced Synthesis (HAS) recently announced the planned acquisition of Cerbios-Pharma (Cerbios), a globally recognized manufacturer of chemical and biological APIs, including antibody-drug conjugates (ADCs).
US contract development and manufacturing organization (CDMO) Veranova has initiated an expansion of its antibody-drug conjugate (ADC) and highly potent active pharmaceutical ingredient (HPAPI) development and manufacturing capabilities at its US facility in Devens, Massachusetts.
UK-headquartered contract development and manufacturing organization (CDMO) Sterling Pharma Solutions has invested $3 million at its US facility in Germantown, WI, to expand the company’s integrated antibody-drug conjugate (ADC) development and manufacturing capabilities.
Olon Group is building a state-of-the-art High Potency Active Pharmaceutical Ingredient (HPAPI) suite at its Olon USA site in Concord, Ohio. This expands the company's capabilities for handling HPAPI, with investments totaling around €40 million ($43 million) in recent years.
Farmabios, a company of the Axplora group founded in 2022, has received the cGMP approval from AIFA (national public body regulating medicines for human use in Italy) for the first line of its new production unit at Gropello Cairoli, Italy, expanding its large scale manufacturing capabilities for high potent active pharmaceutical ingredients (HPAPIs) and steroids.
Clear incentive for drug manufacturers to equip their production facilities with the capacity to process highly potent active pharmaceutical ingredients (HPAPIs). HPAPIs now account for 25% of all drugs produced globally, with some analysts projecting that it will reach a value of $40 billion by 2027.
Lonza has completed of the expansion of its Highly Potent API (HPAPI) multipurpose suite at the Basel-based CDMO’s alpine production site in Visp, Switzerland, adding development and manufacturing capacity for ADC payloads.
The Life Science business segment of German pharmaceuticals, chemicals and life sciences group Merck has widened its US plant for high-potent active pharmaceutical ingredients (HPAPIs) at Verona, near Madison, Wisconsin to 6,500 m2.
Interview with Giovanna Libralon, Senior Director Commercial Development Small Molecules at Lonza.
DCAT Value Chain Insights rounds up recent expansion activity for highly potent drug substances and drug products.
The pharmaceutical industry is increasingly focused on the development of specialized drug products with new treatment modalities, including previously undruggable targets for oncology and other areas.
For biopharma leaders it is more critical than ever to secure the capabilities to contain, handle, develop and manufacture highly potent APIs.
Cerbios has appointed Francesca Scarpitta as director of the company’s high potency active ingredients (HPAIs) production units.
Lugano, Switzerland-based chemical and biological API manufacturer Cerbios announced that its board of directors has approved the installation of a new production line in its building dedicated for high potency active ingredients (HPAIs).
